Zepbound has no set time limit. The FDA approved it for chronic weight management, which means it’s designed to be taken long-term, potentially for life. Medical guidelines from the American Diabetes Association reinforce this, stating that obesity medications should be continued after reaching weight goals to maintain health benefits, since stopping often leads to weight regain. The longest clinical trial data currently available extends to 104 weeks (two years), showing a favorable safety profile throughout.
Why Long-Term Use Is the Standard
Obesity is classified as a chronic disease, similar to high blood pressure or diabetes. Just as you wouldn’t stop taking blood pressure medication once your numbers improved, the same logic applies to Zepbound. The medication works by mimicking two gut hormones that regulate appetite, blood sugar, and fat storage. When you stop taking it, those signals return to their previous levels, and the biological drivers of weight gain come back.
The clinical evidence on this is striking. In the SURMOUNT-4 trial, participants took Zepbound for 36 weeks, then half were switched to a placebo for another year. Among those who stopped the medication, 82% regained more than a quarter of their lost weight. About a third regained 50% to 75% of what they’d lost, and nearly a quarter gained back 75% or more. The group that continued taking Zepbound maintained their results.
What the Clinical Trial Data Covers
The most relevant safety data comes from trials lasting 72 to 104 weeks. The SURMOUNT-1 trial ran for 72 weeks and showed good long-term tolerability. The SURPASS-4 trial, conducted in people with type 2 diabetes, ran for a full two years. In both, gastrointestinal side effects were the most common issue but were generally mild to moderate, and serious adverse events were rare (about 9.3% across trials).
There is no FDA-imposed maximum duration. Your prescriber will periodically assess whether the medication is still appropriate based on your response and health status, but the expectation built into the approval is that most people will stay on it.
Side Effects Over Time
The side effects that make the first few weeks rough tend to fade. Nausea is the most common, affecting a large majority of users in clinical trials, but it typically starts within the first two weeks and resolves within four to six weeks. Diarrhea follows a similar pattern, usually clearing up within three to six weeks. Constipation can take a bit longer to resolve, sometimes six to eight weeks.
Most adverse events occur during the first six weeks of treatment, particularly during dose increases. After your body adjusts to your maintenance dose, side effects decrease considerably. This is one reason the titration schedule is gradual: you start at 2.5 mg for four weeks, move to 5 mg, and can increase by 2.5 mg increments every four weeks after that. Reaching the maximum 15 mg dose takes about 20 weeks.
A small percentage of users (about 7%) develop gallstones, which tend to appear after eight or more weeks and can persist. Pancreatitis occurs in roughly 5% of cases. If you develop severe or persistent abdominal pain, especially pain that radiates to your back, that warrants prompt medical attention.
The Weight Loss Plateau
Weight loss on Zepbound doesn’t continue indefinitely at the same pace. Most people see their progress slow between weeks 24 and 36, depending on starting weight. By week 72, nearly 90% of participants in clinical trials had plateaued. This is normal and expected. It doesn’t mean the medication has stopped working. At that point, Zepbound is functioning as a maintenance tool, helping your body hold at its new weight rather than driving further loss.
Some people wonder whether hitting a plateau means they should stop. The SURMOUNT-4 data answers that clearly: stopping after a plateau leads to significant regain. Continuing the medication preserves the metabolic benefits even when the scale isn’t moving.
Muscle Loss During Treatment
One concern with long-term use is the loss of lean body mass that accompanies any significant weight loss. In the SURPASS-3 MRI substudy, participants on Zepbound for 52 weeks showed measurable reductions in muscle volume. However, when researchers compared these changes to what would be expected from weight loss in the general population, the difference was negligible. In other words, the muscle loss appears to be a consequence of losing weight itself, not something unique to the drug. Resistance training during treatment is widely recommended to minimize this effect.
Thyroid and Pancreatic Monitoring
Zepbound carries a boxed warning about thyroid tumors. In animal studies, drugs in this class caused a specific type of thyroid cancer called medullary thyroid carcinoma. Whether this applies to humans isn’t established, but the medication is contraindicated if you have a personal or family history of that cancer or a condition called Multiple Endocrine Neoplasia syndrome type 2. You should be aware of symptoms like a lump in your neck, difficulty swallowing, or persistent hoarseness.
Routine thyroid screening specifically because of Zepbound isn’t recommended, as the tests aren’t specific enough and could lead to unnecessary procedures. Pancreatic enzyme levels do rise during treatment (20% to 35% above baseline), but elevated enzymes alone, without symptoms, don’t indicate a problem.
Staying On vs. Stepping Down
Your maintenance dose doesn’t have to be the highest one. The FDA lists 5 mg, 10 mg, and 15 mg as maintenance options. Some people achieve their goals at a lower dose and stay there. The 2.5 mg starting dose is the only one explicitly not intended for long-term use.
If you and your prescriber decide to stop Zepbound, there’s no required tapering protocol, but you should expect some weight regain. The degree varies by individual, but the trial data suggests most people will regain a substantial portion of lost weight within a year of stopping. Planning for increased attention to diet and exercise during that transition can help blunt the effect, though it rarely fully compensates for the medication’s absence.